Insulet Co. (NASDAQ:PODD) Shares Acquired by Trexquant Investment LP

Trexquant Investment LP lifted its holdings in Insulet Co. (NASDAQ:PODD) by 25.9% during the fourth quarter, Holdings Channel reports. The fund owned 68,045 shares of the medical instruments supplier’s stock after buying an additional 13,996 shares during the quarter. Trexquant Investment LP’s holdings in Insulet were worth $17,765,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in PODD. SBI Securities Co. Ltd. acquired a new stake in Insulet during the 4th quarter worth about $36,000. SRS Capital Advisors Inc. boosted its stake in shares of Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock worth $49,000 after buying an additional 56 shares during the last quarter. TD Private Client Wealth LLC grew its holdings in Insulet by 32.6% during the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after acquiring an additional 56 shares during the period. Friedenthal Financial purchased a new position in Insulet during the fourth quarter valued at approximately $57,000. Finally, Assetmark Inc. lifted its holdings in Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock valued at $69,000 after acquiring an additional 246 shares during the period.

Insulet Stock Up 0.2 %

PODD stock opened at $263.18 on Wednesday. The company has a market cap of $18.48 billion, a price-to-earnings ratio of 45.45, a PEG ratio of 3.62 and a beta of 1.29. The firm has a 50-day moving average of $271.17 and a two-hundred day moving average of $259.40. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $289.46. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating the consensus estimate of $1.00 by $0.15. The firm had revenue of $597.50 million during the quarter, compared to analysts’ expectations of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. As a group, analysts forecast that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Royal Bank of Canada assumed coverage on shares of Insulet in a report on Thursday, March 6th. They set an “outperform” rating and a $340.00 target price for the company. Canaccord Genuity Group upped their price objective on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Wells Fargo & Company raised their target price on Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Raymond James reaffirmed an “outperform” rating and issued a $328.00 price target (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st. Finally, JPMorgan Chase & Co. raised their price objective on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a report on Thursday, December 12th. Four analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $292.06.

Insider Transactions at Insulet

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the firm’s stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now owns 3,231 shares in the company, valued at $888,525. This trade represents a 36.10 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.